Report: Pipeline and Commercial Insight: Osteoporosis Novel agents to battle for payer acceptance TOC

EXECUTIVE SUMMARY

Scope of the analysis
Datamonitor insight into the osteoporosis market
Key metrics
Contributing experts
Related reports

PATIENT POTENTIAL

Definition of osteoporosis
- Etiology
- Symptoms
- Diagnosis and treatment rates
Patient segmentation
- Disease severity
- Gender
Epidemiology
- Seven major markets
- BRIC countries
- Rest of the world
Current treatment options
- Bisphosphonates
- Selective estrogen receptor modulators
- Parathyroid hormones
- Calcitonins
- Dual acting bone agents
- Vitamin D and analogs
- Calcium
Clinical unmet need in osteoporosis
- Need for improved anabolic therapies
- Efficacy at the hip
- Increased compliance
- Better side-effect profile and safety
- Efficacy for spine fractures
Environmental unmet need in osteoporosis
- Increased patient identification
- Increased prevention of osteoporosis
- Increase male osteoporosis awareness
- Target product profile

MARKET OVERVIEW

Market definition for this report
Seven major markets current and future market assessment
- The osteoporosis market will continue to grow up to 2018 despite generic alendronate penetration
Rest of the world snapshot
- The global osteoporosis market continues to display strong growth
- The rest of the world accounted for 25.4% of the osteoporosis global market in 2008
- The rest of the world outstrips the seven major markets in terms of volume
- Other European countries form the largest region, but the BRIC countries are by far the fastest-growing
- Calcium accounts for over 90% of the total volume sales in the rest of the world
Patient acquisition process
- Introduction
- Patient care path
- Points of influence in the patient care path
- Drivers of drug choice
US formulary tier status for leading brands
EU osteoporosis reimbursement policies
Brand dynamics - bisphosphonates
- Class overview
- Fosamax/Fosamax Plus D (alendronate, Merck & Co.)
- Actonel/Actonel with Calcium (risedronic acid; Procter and Gamble/Sanofi-Aventis)
- Bonviva/Boniva (ibandronic acid, Roche/GlaxoSmithKline)
- Aclasta (zoledronic acid, Novartis)
- Bonoteo/Recalbon (minodronic acid, Astellas/Ono Pharmaceutical)
- Brand dynamics - selective estrogen receptor modulators
- Evista (raloxifene, Eli Lilly)
Brand dynamics - parathyroid hormones
- Forteo (teriparatide, Eli Lilly)
- Preotact (full-length parathyroid hormone PTH 1-84, NPS/Nycomed)
Brand dynamics - dual acting bone agents
- Protelos (strontium ranelate, Servier)
Brand dynamics - calcitonins
- Miacalcic (calcitonin-salmon, Novartis)
- Fortical (calcitonin-salmon, Unigene)

PIPELINE OVERVIEW AND R&D DYNAMICS

Pipeline overview
- Comparative forecasts
- Datamonitor pipeline assessment summary
Key companies involved in the disease osteoporosis pipeline
- Companies currently involved in the market are seeking novel drug developments to maintain their market share
- Amgen - a future key market player
Clinical trial design in osteoporosis
- Preclinical trials

LATE-STAGE DRUG ANALYSIS AND FORECASTS

Definition of current comparator therapies
- Overall market comparator - Fosamax (alendronate, Merck & Co)
- Individual class comparators
Bisphosphonates - key late-stage pipeline
- Pipeline summary
- Comparative forecasts
- EX101 (alendronate; EffRx)
- Almerol (MER-103, alendronate; Merrion)
- Late-stage development compounds recently discontinued
Selective estrogen receptor modulators - key late-stage pipeline
- Pipeline summary
- Comparative forecasts
- Fablyn (lasofoxifene; Pfizer/Ligand)
- Conbriza/Viviant (bazedoxifene; Wyeth)
- Aprela (bazedoxifene with conjugated estrogens; Wyeth)
- Arzoxifene (LY353381, Eli Lilly)
Parathyroid hormones and analogs - key late-stage pipeline
- Pipeline summary
- Comparative forecasts
- ZT-031 (previously Ostabolin-C, Zelos Therapeutics)
- ZP-PTH (hPTH1-34, Zosano Pharma)
Calcitonins - key late-stage pipeline
- Pipeline summary
- Capsitonin (BN-002, Bone medical)
- Drug overview
Other drugs - key late-stage pipeline
- Pipeline summary
- Comparative forecasts
- Denosumab (AMG-162, Amgen)
- Odanacatib (MK0822, Merck & Co)
- Eldecalcitol (ED-71, Chugai/Taisho)
Key early-stage compounds in osteoporosis

BIBLIOGRAPHY

Journal papers, books, and conference abstracts
Websites
Datamonitor reports

APPENDIX A

Data definitions, limitations and assumptions
- Standard units
- Derivation of sales forecasts and pricing trends
Methodology
- Indication-specific sales calculations

APPENDIX B

Contributing experts

TABLES

Table: Sales forecast for key marketed brands in osteoporosis across the seven major markets, 2008 - 2018
Table: Sales forecast for pipeline products in osteoporosis in the seven major markets ($m), 2009 - 2018
Table: Risk factors (-) and protective factors (+) for axial and appendicular bone mineral density in women aged 65 years and over
Table: Fracture risk assessment tool (FRAX) questionnaire, 2009
Table: 10-year probability of osteoporotic fractures (%), according to BMD T-score at the femoral neck in women aged 65 years from the UK n
Table: Causes of male osteoporosis
Table: Summary of osteoporosis prevalence studies in the seven major markets, 2009
Table: Osteopenia epidemiology across the seven major markets, 2009
Table: Osteoporosis epidemiology across the seven major markets, 2009
Table: Severe osteoporosis epidemiology across the seven major markets, 2009
Table: Summary of osteoporosis epidemiology of women over 50 years of age across the seven major markets, 2009
Table: Estimated osteoporosis epidemiology of women over 50 years of age across the seven major markets, 2020
Table: Prevalence of osteopenia in men over 50 across the seven major markets, 2009
Table: Prevalence of osteoporosis in men over 50 across the seven major markets, 2009
Table: Estimated female hip fracture prevalence in Brazil, 2009, 2015 and 2020
Table: Estimated male hip fracture prevalence in Brazil, 2009, 2015 and 2020
Table: Estimated number of female hip fractures in Russia, North America and Europe, 1990, 2025, and 2050
Table: Estimated number of male hip fractures in Russia, North America, Europe, 1990, 2025 and 2050
Table: Female prevalence of osteopenia in India, 2009, 2015 and 2020
Table: Female prevalence of osteoporosis in India, 2009, 2015 and 2020
Table: Estimated number of hip fractures in Chinese women, 2009, 2015 and 2020
Table: Estimated female osteoporosis prevalence in China, 2009, 2015, 2020
Table: Estimated male osteoporosis prevalence in China, 2009, 2015, 2020
Table: Estimated number of osteoporotic fractures by site, in men and women aged 50 years and over by region, in 2000
Table: Key medications currently approved for osteoporosis treatment across the seven major markets, 2009
Table: Key marketed bisphosphonates in osteoporosis across the seven major markets, 2009
Table: Marketed selective estrogen receptor modulators in osteoporosis across the seven major markets, 2009
Table: Marketed parathyroid hormones in osteoporosis, 2009
Table: Key marketed calcitonins in osteoporosis across the seven major markets, 2009
Table: Key dual acting bone agents marketed across the seven major markets, 2009
Table: Summary of key drugs in osteoporosis side effects and safety profiles, 2009
Table: Osteoporosis target product profile, 2009
Table: Summary of therapeutic classes in osteoporosis by ATC code, 2009
Table: Summary of the ICD-10 codes used to derive osteoporosis-specific sales from each brand
Table: Regional osteoporosis market sales ($m) dynamics across the seven major markets, 2004 - 2018
Table: ATC class sales ($m) in osteoporosis across the seven major markets , 2004 - 2018
Table: Key marketed brand sales ($m) in osteoporosis across the seven major markets, 2004 - 08
Table: Sales forecast for key marketed brands in osteoporosis across the seven major markets, 2008 - 2018
Table: Key events impacting the osteoporosis market, 2009 - 2018
Table: Global sales ($m) dynamics of the osteoporosis market, 2004 - 08
Table: Regional split of the global osteoporosis market sales, 2004 - 08
Table: Global osteoporosis market volume (IMS standard unit) sales by ATC class, 2008
Table: Representative formulary tier status in the US for leading brands in osteoporosis, 2009
Table: EU osteoporosis treatment reimbursement policies, 2008
Table: Fosamax: key facts, 2009
Table: Impacting factors on the revenues of Fosamax brand franchise, 2009 - 2018
Table: Actonel: key facts, 2009
Table: Impacting factors on the revenues of the Actonel brand franchise, 2009 - 2018
Table: Bonviva: key facts, 2009
Table: Impacting factors on the revenues of Bonviva brand franchise, 2009 - 2018
Table: Aclasta: key facts, 2009
Table: Impacting factors on the revenues of Aclasta, 2009 - 2018
Table: Bonoteo: key facts, 2009
Table: Impacting factors on the revenues of Bonoteo, 2009 - 2018
Table: Evista: key facts, 2009
Table: Impacting factors on the revenues of Evista, 2009 - 2018
Table: Forteo: key facts, 2009
Table: Impacting factors on the revenues of Forteo, 2009 - 2018
Table: Preotact: key facts, 2009
Table: Impacting factors on the revenues of Preotact, 2009 - 2018
Table: Protelos: key facts, 2009
Table: Impacting factors on the revenues of Protelos , 2009 - 2018
Table: Miacalcic: key facts, 2009
Table: Impacting factors on the revenues of Miacalcic , 2009 - 2018
Table: Fortical: key facts, 2009
Table: Impacting factors on the revenues of Fortical, 2009 - 2018
Table: R&D drug pipeline for osteoporosis, 2009
Table: Sales forecast for pipeline products in osteoporosis in the seven major markets ($m), 2009 - 2018
Table: Amgen' s osteoporosis pipeline, 2009
Table: FDA and EMEA preclinical study requirements for osteoporosis drug approval, 2009
Table: Summary of the key FDA and EMEA Phase III clinical trial requirements in osteoporosis, 2009
Table: FDA recommended primary efficacy points for prevention and treatment studies
Table: Biomarkers for bone formation and bone resorption, 2009
Table: Defining the gold standard for osteoporosis: key clinical trial results for Fosamax
Table: Key efficacy data for Fosamax (alendronate), Evista (raloxifene) Forteo (teriparatide) and Miacalcic (calcitonin-salmon) in the treatment of osteoporosis
Table: Key products in the late-stage bisphosphonate pipeline for osteoporosis, 2009
Table: EX101: key facts, 2009
Table: Sales forecasts ($m) for EX101 in the seven major markets, 2011 - 18
Table: Impacting factors on the revenues of EX101, 2011 - 18
Table: Almerol: key facts, 2009
Table: Sales ($m) forecasts for Almerol in the seven major markets, 2014 - 18
Table: Impacting factors on the revenues of Almerol, 2014 - 18
Table: Recently discontinued late-stage bisphosphonates, 2009
Table: Key products in the late-stage selective estrogen receptor modulator (SERM) pipeline for osteoporosis, 2009
Table: Fablyn: key facts, 2009
Table: Summary of key Phase III clinical trials for Fablyn (lasofoxifene)
Table: Cumulative outcomes of 3 years treatment with Fablyn (lasofoxifene) versus placebo (rate per 1,000 subjects over 3 years)
Table: Sales ($m) forecasts for Fablyn in the seven major markets, 2010 - 18
Table: Impacting factors on the revenues of Fablyn, 2010 - 18
Table: Conbriza: key facts, 2009
Table: Summary of key Phase III clinical trials for Conbriza (bazedoxifene)
Table: Summary of fracture data from Conbriza (bazedoxifene) Phase III clinical trial
Table: Sales forecasts for Conbriza in the seven major markets, 2009 - 2018 ($m)
Table: Impacting factors on the revenues of Conbriza, 2009 - 2018
Table: Aprela: key facts, 2009
Table: Aprela forecast osteoporosis sales ($m) across the seven major markets, 2011 - 2018
Table: Impacting factors on the revenues of Aprela, 2011 - 18
Table: Arzoxifene: key facts, 2009
Table: Summary of key clinical trials for arzoxifene
Table: Arzoxifene Phase III study results, 2009
Table: Phase III trial in postmenopausal women to determine the efficacy of arzoxifene on fracture risk and breast cancer, 2009
Table: Arzoxifene forecast osteoporosis sales ($m) across the seven major markets, 2012 - 2018
Table: Impacting factors on the revenues of arzoxifene, 2012 - 18
Table: Key products in the late-stage parathyroid hormone (PTH) pipeline for osteoporosis, 2009
Table: ZT-031: key facts, 2009
Table: ZT-031 forecast osteoporosis sales ($m) across the seven major markets, 2014 - 18
Table: Impacting factors on the revenues of ZT-031, 2014 - 18
Table: ZP-PTH: key facts, 2009
Table: ZP-PTH forecast osteoporosis sales ($m) across the seven major markets, 2015 - 18
Table: Impacting factors on the revenues of ZP-PTH, 2015 - 18
Table: Key products in the late-stage calcitonin pipeline for osteoporosis, 2009
Table: Capsitonin: key facts, 2009
Table: Capsitonin forecast osteoporosis sales ($m) across the seven major markets, 2013 - 18
Table: Impacting factors on the revenues of capsitonin, 2013 - 18
Table: Key products in the late-stage ' other treatments' pipeline for osteoporosis, 2009
Table: Denosumab: key facts, 2009
Table: Summary of key denosumab studies, 2009
Table: Denosumab Phase III DECIDE clinical trial results
Table: Japanese Phase III trial in postmenopausal women to determine the efficacy of denosumab in reducing fracture risk, 2009
Table: Denosumab forecast osteoporosis sales ($m) across the seven major markets, 2010 - 18
Table: Impacting factors on the revenues of denosumab, 2010 - 18
Table: Odanacatib: key facts, 2009
Table: Phase III trial in postmenopausal women to determine the efficacy of odanacatib in reducing fracture risk, 2009
Table: Phase III trial in postmenopausal women to determine the efficacy of odanacatib on bone mineral density (BMD), 2009
Table: Phase III trial in postmenopausal women to determine the safety and efficacy of odanacatib on bone mineral density (BMD), 2009
Table: Odanacatib forecast osteoporosis sales ($m) across the seven major markets, 2014 - 18
Table: Impacting factors on the revenues of odanacatib, 2014 - 18
Table: Eldecalcitol: key facts, 2009
Table: Summary of key clinical trials for eldecalcitol
Table: Eldecalcitol forecast osteoporosis sales ($m) across the seven major markets, 2011 - 18
Table: Impacting factors on the revenues of eldecalcitol, 2011 - 18
Table: Summary of products in preclinical trials for the treatment of osteoporosis, 2009
Table: Patent expiry dates for key marketed brands in osteoporosis in the US and Japan, 2009
Table: Patent expiry dates for key marketed brands in osteoporosis in the five major European market regions, 2009
Table: Estimated launch dates for key late stage pipeline products and marketed brands in the seven major market regions, 2009 - 2018
Table: Datamonitor drug assessment parameters for pipeline bisphosphonate products, 2009
Table: Datamonitor drug assessment parameters for pipeline selective estrogen receptor modulators (SERMs) products, 2009
Table: Datamonitor drug assessment parameters for pipeline parathyroid hormone (PTH) products, 2009
Table: Datamonitor drug assessment parameters for pipeline calcitonins products, 2009
Table: Datamonitor drug assessment parameters for pipeline other products, 2009

FIGURES

Figure: Development of osteoporotic bone
Figure: Osteoporotic fractures occur most commonly at the spine, hip and wrist
Figure: Potentially osteoporotic patients who receive each method of additional diagnostic technique, 2008
Figure: Treatment of Caucasian women aged 60 years or older with osteoporosis or vertebral fractures by primary care physicians, by drug type, 1993 - 97
Figure: World Health Organization classification of osteoporotic bone loss
Figure: Average prevalence according to osteoporosis severity across the seven major markets, 2008
Figure: Female osteoporosis epidemiology by severity of women across the seven major markets, 2009
Figure: Increase of osteoporosis prevalence by severity, 2009 - 2020
Figure: Hip fracture prevalence across the BRIC countries, 2009 - 2020
Figure: Estimated number of male hip fractures in Russia, North America, Europe, 1990, 2025 and 2050
Figure: Bisphosphonate mechanism of action
Figure: Selective estrogen receptor modulator' s mechanism of action in osteoporosis, 2009
Figure: Key clinical unmet needs in osteoporosis, 2009
Figure: Percentage of patients discontinuing pharmacological treatment due to non-compliance at different times across the seven major markets, 2008
Figure: Key environmental unmet needs in osteoporosis, 2009
Figure: Osteoporosis market sales ($m) across the seven major markets, 2004 - 2018
Figure: Osteoporosis market sales dynamics ($m) across the seven major markets, 2004 - 2018
Figure: Osteoporosis market volume sales (IMS standard units) across the seven major markets, 2004 - 08
Figure: Regional osteoporosis market value sales ($m) in the across the seven major markets, 2004 - 08
Figure: Forecast regional osteoporosis market value sales ($m) across the seven major markets, 2008 - 2018
Figure: Regional osteoporosis market volume sales (IMS standard units sold) across the seven major markets, 2004 - 08
Figure: Forecast regional osteoporosis market volume sales (IMS standard units sold) across the seven major markets, 2008 - 2018
Figure: ATC class sales ($m) in osteoporosis across the seven major markets, 2004 - 08
Figure: ATC class sales ($m) in osteoporosis across the seven major markets, 2008 - 2018
Figure: Key marketed brand sales ($m) dynamics in osteoporosis across the seven major markets, 2004 - 08
Figure: Global osteoporosis market sales ($m), 2004 - 08
Figure: Global osteoporosis market sales ($m) dynamics, 2004 - 08
Figure: Global osteoporosis market volume (IMS standard units sold) and value ($) sales, 2008
Figure: Rest of the world osteoporosis market sales value ($m), 2004 - 08
Figure: Rest of the world osteoporosis market regional dynamics, 2004 - 08
Figure: Rest of the world osteoporosis market ATC class dynamics, 2004 - 08
Figure: Osteoporosis patient care path in the seven major markets, 2009
Figure: Key drivers of drug choice in osteoporosis across the seven major markets, 2008
Figure: Assessment of formulary status in osteoporosis in the US, 2009
Figure: Overall Fosamax branded franchise sales ($m) in osteoporosis across the seven major markets, 2004 - 08
Figure: Fosamax franchise: SWOT analysis, 2009
Figure: Fosamax brand franchise osteoporosis sales ($m) forecast across the seven major markets, 2008 - 2018
Figure: Fosamax Plus D osteoporosis sales ($m) across the seven major markets, 2004 - 2018
Figure: Actonel branded franchise sales ($m) in osteoporosis across the seven major markets, 2004 - 08
Figure: Actonel franchise: SWOT analysis, 2009
Figure: Actonel brand franchise osteoporosis sales ($m) forecast across the seven major markets, 2008 - 2018
Figure: Actonel and Actonel with Calcium osteoporosis sales ($m) forecast across the seven major markets, 2008 - 2018
Figure: Bonviva branded franchise market sales ($m) in osteoporosis across the seven major markets, 2004 - 08
Figure: Bonviva franchise: SWOT analysis, 2009
Figure: Bonviva brand franchise osteoporosis sales ($m) forecast across the seven major markets, 2008 - 2018
Figure: Bonviva oral and intravenous (IV) osteoporosis sales ($m) forecast across the seven major markets, 2008 - 2018
Figure: Aclasta market sales ($m) in osteoporosis across the seven major markets, 2006 - 08
Figure: Aclasta: SWOT analysis, 2009
Figure: Aclasta forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
Figure: Bonoteo: SWOT analysis, 2009
Figure: Bonoteo forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
Figure: Evista' s sales dynamics in osteoporosis across the seven major markets, 2005 - 08
Figure: Evista: SWOT analysis, 2009
Figure: Evista forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
Figure: Evista' s regional osteoporosis sales ($m) across the seven major markets, 2004 - 2018
Figure: Forteo' s sales in osteoporosis across the seven major markets, 2004 - 08
Figure: Forteo: SWOT analysis, 2009
Figure: Forteo forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
Figure: Forteo regional osteoporosis sales ($m) across the seven major markets, 2004 - 2018
Figure: Preotact' s sales in osteoporosis across the seven major markets, 2006 - 08
Figure: Preotact: SWOT analysis, 2009
Figure: Preotact forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
Figure: Preotact regional osteoporosis sales ($m) across the seven major markets, 2007 - 2018
Figure: Protelos sales ($m) in osteoporosis across the seven major markets, 2005 - 08
Figure: Protelos: SWOT analysis, 2009
Figure: Protelos forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
Figure: Protelos regional osteoporosis sales ($m) across the seven major markets, 2005 - 2018
Figure: Miacalcic sales ($m) in osteoporosis across the seven major markets, 2004 - 08
Figure: Miacalcic: SWOT analysis, 2009
Figure: Miacalcic franchise forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
Figure: Fortical sales ($m) in osteoporosis across the seven major markets, 2004 - 08
Figure: Fortical: SWOT analysis, 2009
Figure: Fortical forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
Figure: Pipeline drugs for osteoporosis by development phase, 2009
Figure: Pipeline drugs for osteoporosis by class, 2009
Figure: Pipeline drugs for osteoporosis by development phase and class of drug, 2009
Figure: Pipeline drugs for osteoporosis by mechanism of action, 2009
Figure: Datamonitor drug assessment summary of pipeline bisphosphonates for osteoporosis, 2009
Figure: Datamonitor drug assessment summary of pipeline selective estrogen receptor modulator (SERM) treatments for osteoporosis, 2009
Figure: Datamonitor drug assessment summary of pipeline parathyroid hormone (PTH) treatments for osteoporosis, 2009
Figure: Datamonitor drug assessment summary of pipeline calcitonin treatments for osteoporosis, 2009
Figure: Datamonitor drug assessment summary of other pipeline treatments for osteoporosis, 2009
Figure: Guide to the Food and Drug Administration (FDA) action on new drug applications for osteoporosis
Figure: Datamonitor drug assessment summary of bisphosphonate treatments for osteoporosis, 2009
Figure: Sales ($m) forecast for key pipeline drugs for osteoporosis bisphosphonates in the seven major markets, 2008 - 2018
Figure: EX101: SWOT analysis, 2009
Figure: Datamonitor drug assessment summary of EX101 for osteoporosis, 2009
Figure: EX101 forecast osteoporosis sales ($m) across the seven major markets, 2008 - 2018
Figure: Almerol: SWOT analysis, 2009
Figure: Datamonitor drug assessment summary of Almerol for osteoporosis, 2009
Figure: Almerol forecast osteoporosis sales ($m) across the seven major markets, 2014 - 18
Figure: Datamonitor drug assessment summary of selective estrogen receptor modulators (SERMs) treatments for osteoporosis, 2009
Figure: Sales ($m) forecast for key pipeline drugs for osteoporosis selective estrogen receptor modulators (SERM) in the seven major markets, 2008 - 2018
Figure: Fablyn: SWOT analysis, 2009
Figure: Postmenopausal evaluation and risk-reduction with lasofoxifene (PEARL) clinical trial design
Figure: Datamonitor drug assessment summary of Fablyn for osteoporosis, 2009
Figure: Fablyn forecast osteoporosis sales ($m) across the seven major markets, 2009 - 2018
Figure: Conbriza: SWOT analysis, 2009
Figure: Conbriza (bazedoxifene) clinical trial design and results
Figure: Conbriza (bazedoxifene) Phase III clinical trial design
Figure: Datamonitor drug assessment summary of Conbriza for osteoporosis, 2009
Figure: Conbriza forecast osteoporosis sales ($m) across the seven major markets, 2009 - 2018
Figure: Aprela: SWOT analysis, 2009
Figure: Datamonitor drug assessment summary of Aprela for osteoporosis, 2009
Figure: Aprela forecast osteoporosis sales ($m) across the seven major markets, 2011 - 2018
Figure: Arzoxifene: SWOT analysis, 2009
Figure: Datamonitor drug assessment summary of arzoxifene for osteoporosis, 2009
Figure: Arzoxifene forecast osteoporosis sales ($m) across the seven major markets, 2011 - 2018
Figure: Datamonitor drug assessment summary of parathyroid hormone (PTH) treatments for osteoporosis, 2009
Figure: Sales ($m) forecast for key pipeline drugs for osteoporosis parathyroid hormone (PTH) in the seven major markets, 2008 - 2018
Figure: ZT-031: SWOT analysis, 2009
Figure: Datamonitor drug assessment summary of ZT-031 for osteoporosis, 2009
Figure: ZT-031 forecast osteoporosis sales ($m) across the seven major markets, 2013 - 18
Figure: ZP-PTH: SWOT analysis, 2009
Figure: Datamonitor drug assessment summary of ZP-PTH for osteoporosis, 2009
Figure: ZP-PTH forecast osteoporosis sales ($m) across the seven major markets, 2014 - 18
Figure: Datamonitor drug assessment summary of calcitonins treatments for osteoporosis, 2009
Figure: Capsitonin: SWOT analysis, 2009
Figure: Datamonitor drug assessment summary of capsitonin for osteoporosis, 2009
Figure: Capsitonin forecast osteoporosis sales ($m) across the seven major markets, 2013 - 18
Figure: Datamonitor drug assessment summary of other treatments for osteoporosis, 2009
Figure: Sales ($m) forecast for key pipeline drugs for other osteoporosis treatments in the seven major markets, 2008 - 2018
Figure: Denosumab: SWOT analysis, 2009
Figure: Denosumab Phase III DECIDE clinical trial design
Figure: Datamonitor drug assessment summary of denosumab for osteoporosis, 2009
Figure: Denosumab forecast osteoporosis sales ($m) across the seven major markets, 2010 - 18
Figure: Odanacatib: SWOT analysis, 2009
Figure: Datamonitor drug assessment summary of odanacatib for osteoporosis, 2009
Figure: Odanacatib forecast osteoporosis sales ($m) across the seven major markets, 2014 - 18
Figure: Eldecalcitol: SWOT analysis, 2009
Figure: Datamonitor drug assessment summary of eldecalcitol for osteoporosis, 2009
Figure: Eldecalcitol forecast osteoporosis sales ($m) across the seven major markets, 2011 - 18
Figure: Datamonitor drug assessment summary of other treatments for osteoporosis, 2009

Pipeline and Commercial Insight: Osteoporosis Novel agents to battle for payer acceptance

Table of Contents

EXECUTIVE SUMMARY

PATIENT POTENTIAL

MARKET OVERVIEW

PIPELINE OVERVIEW AND R&D DYNAMICS

LATE-STAGE DRUG ANALYSIS AND FORECASTS

BIBLIOGRAPHY

APPENDIX A

APPENDIX B

TABLES

FIGURES